AOCNP® — Advanced Oncology Certified Nurse
Practitioner Exam| YEAR 2026–2027 | Comprehensive
150-Question Practice Test with Answers & Rationales|
Pdf Access ALREADY GRADED A+.
PART I — ONCOLOGY FOUNDATIONS & DIAGNOSTICS
1. Which characteristic most strongly distinguishes a malignant neoplasm from a benign
neoplasm?
A. Slow growth
B. Encapsulation
C. Invasion and metastatic potential
D. Well-defined borders
Answer: C. Invasion and metastatic potential
Rationale: Malignant tumors can invade surrounding tissues and spread to distant sites,
whereas benign tumors generally remain localized.
2. What is the primary purpose of cancer staging?
A. Determine the patient's blood type
B. Determine the extent of disease
C. Determine the patient's pain tolerance
D. Determine whether the patient has an infection
Answer: B. Determine the extent of disease
Rationale: Staging describes the extent and spread of cancer and is essential for treatment
planning and prognostic assessment.
3. In the TNM system, the "M" category describes:
A. Mitotic activity
B. Molecular classification
,C. Distant metastasis
D. Marrow function
Answer: C. Distant metastasis
Rationale: T describes the primary tumor, N describes regional lymph nodes, and M describes
distant metastasis.
4. Which test provides definitive histologic confirmation of most solid malignancies?
A. CBC
B. Biopsy
C. ECG
D. Serum sodium
Answer: B. Biopsy
Rationale: Tissue biopsy permits microscopic evaluation and generally provides the definitive
pathologic diagnosis.
5. What is the purpose of molecular profiling of a tumor?
A. Determine the patient's blood pressure
B. Identify potentially actionable molecular alterations
C. Determine the patient's pain score
D. Replace all pathology evaluation
Answer: B. Identify potentially actionable molecular alterations
Rationale: Molecular testing can identify genomic alterations that may influence prognosis,
targeted therapy, immunotherapy, or clinical-trial eligibility.
6. Which biomarker is associated with breast cancer and may guide targeted treatment?
A. HER2
B. PSA
C. CA 19-9
D. AFP
Answer: A. HER2
,Rationale: HER2 overexpression or amplification identifies a subset of breast cancers that may
respond to HER2-directed therapy.
7. Which tumor marker is commonly associated with prostate cancer?
A. CA-125
B. PSA
C. CEA
D. CA 15-3
Answer: B. PSA
Rationale: Prostate-specific antigen is produced by prostate tissue and is used in prostate
cancer screening and disease monitoring.
8. Which tumor marker is commonly used in monitoring selected patients with ovarian
cancer?
A. CA-125
B. PSA
C. Troponin
D. BNP
Answer: A. CA-125
Rationale: CA-125 can be useful in monitoring certain ovarian cancers, although it is not
sufficiently specific to diagnose ovarian cancer by itself.
9. Which finding warrants evaluation for possible cancer?
A. Persistent unexplained weight loss
B. One episode of sneezing
C. Temporary muscle soreness
D. Mild thirst after exercise
Answer: A. Persistent unexplained weight loss
Rationale: Unexplained weight loss can be a warning sign of malignancy, although many
nonmalignant conditions can produce the same finding.
, 10. Which patient history represents a major modifiable cancer risk factor?
A. Tobacco use
B. Age
C. Genetic ancestry
D. Family history
Answer: A. Tobacco use
Rationale: Tobacco exposure is a major preventable risk factor for numerous cancers.
PART II — BREAST & GYNECOLOGIC ONCOLOGY
11. A patient with newly diagnosed breast cancer has a tumor that is estrogen-receptor
positive. Which therapy may be appropriate?
A. Endocrine therapy
B. Antibiotic monotherapy
C. Anticoagulation alone
D. Radiation to the kidneys
Answer: A. Endocrine therapy
Rationale: Hormone-receptor-positive breast cancers may respond to endocrine therapies such
as tamoxifen or aromatase inhibitors, depending on menopausal status and clinical
circumstances.
12. Which medication is a selective estrogen receptor modulator commonly used in breast
cancer?
A. Tamoxifen
B. Filgrastim
C. Cisplatin
D. Methotrexate
Answer: A. Tamoxifen
Rationale: Tamoxifen blocks estrogen receptor activity in breast tissue and is used in hormone-
receptor-positive breast cancer.
Practitioner Exam| YEAR 2026–2027 | Comprehensive
150-Question Practice Test with Answers & Rationales|
Pdf Access ALREADY GRADED A+.
PART I — ONCOLOGY FOUNDATIONS & DIAGNOSTICS
1. Which characteristic most strongly distinguishes a malignant neoplasm from a benign
neoplasm?
A. Slow growth
B. Encapsulation
C. Invasion and metastatic potential
D. Well-defined borders
Answer: C. Invasion and metastatic potential
Rationale: Malignant tumors can invade surrounding tissues and spread to distant sites,
whereas benign tumors generally remain localized.
2. What is the primary purpose of cancer staging?
A. Determine the patient's blood type
B. Determine the extent of disease
C. Determine the patient's pain tolerance
D. Determine whether the patient has an infection
Answer: B. Determine the extent of disease
Rationale: Staging describes the extent and spread of cancer and is essential for treatment
planning and prognostic assessment.
3. In the TNM system, the "M" category describes:
A. Mitotic activity
B. Molecular classification
,C. Distant metastasis
D. Marrow function
Answer: C. Distant metastasis
Rationale: T describes the primary tumor, N describes regional lymph nodes, and M describes
distant metastasis.
4. Which test provides definitive histologic confirmation of most solid malignancies?
A. CBC
B. Biopsy
C. ECG
D. Serum sodium
Answer: B. Biopsy
Rationale: Tissue biopsy permits microscopic evaluation and generally provides the definitive
pathologic diagnosis.
5. What is the purpose of molecular profiling of a tumor?
A. Determine the patient's blood pressure
B. Identify potentially actionable molecular alterations
C. Determine the patient's pain score
D. Replace all pathology evaluation
Answer: B. Identify potentially actionable molecular alterations
Rationale: Molecular testing can identify genomic alterations that may influence prognosis,
targeted therapy, immunotherapy, or clinical-trial eligibility.
6. Which biomarker is associated with breast cancer and may guide targeted treatment?
A. HER2
B. PSA
C. CA 19-9
D. AFP
Answer: A. HER2
,Rationale: HER2 overexpression or amplification identifies a subset of breast cancers that may
respond to HER2-directed therapy.
7. Which tumor marker is commonly associated with prostate cancer?
A. CA-125
B. PSA
C. CEA
D. CA 15-3
Answer: B. PSA
Rationale: Prostate-specific antigen is produced by prostate tissue and is used in prostate
cancer screening and disease monitoring.
8. Which tumor marker is commonly used in monitoring selected patients with ovarian
cancer?
A. CA-125
B. PSA
C. Troponin
D. BNP
Answer: A. CA-125
Rationale: CA-125 can be useful in monitoring certain ovarian cancers, although it is not
sufficiently specific to diagnose ovarian cancer by itself.
9. Which finding warrants evaluation for possible cancer?
A. Persistent unexplained weight loss
B. One episode of sneezing
C. Temporary muscle soreness
D. Mild thirst after exercise
Answer: A. Persistent unexplained weight loss
Rationale: Unexplained weight loss can be a warning sign of malignancy, although many
nonmalignant conditions can produce the same finding.
, 10. Which patient history represents a major modifiable cancer risk factor?
A. Tobacco use
B. Age
C. Genetic ancestry
D. Family history
Answer: A. Tobacco use
Rationale: Tobacco exposure is a major preventable risk factor for numerous cancers.
PART II — BREAST & GYNECOLOGIC ONCOLOGY
11. A patient with newly diagnosed breast cancer has a tumor that is estrogen-receptor
positive. Which therapy may be appropriate?
A. Endocrine therapy
B. Antibiotic monotherapy
C. Anticoagulation alone
D. Radiation to the kidneys
Answer: A. Endocrine therapy
Rationale: Hormone-receptor-positive breast cancers may respond to endocrine therapies such
as tamoxifen or aromatase inhibitors, depending on menopausal status and clinical
circumstances.
12. Which medication is a selective estrogen receptor modulator commonly used in breast
cancer?
A. Tamoxifen
B. Filgrastim
C. Cisplatin
D. Methotrexate
Answer: A. Tamoxifen
Rationale: Tamoxifen blocks estrogen receptor activity in breast tissue and is used in hormone-
receptor-positive breast cancer.
